Several reports indicate that PPARγ agonists are protective against NAFLD/NASH by reducing inflammation, possibly through inhibiting production of inflammatory cytokines 24, 25, 26, 27, 28, 29. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.